Pronunciation:

(hye al yoor ON i dase)

U.S. Brand Names:

Generic Available:

Use:

Use - Unlabeled/Investigational:

Pregnancy Risk Factor:

Pregnancy Implications:

Lactation:

Contraindications:

Warnings/Precautions:

Adverse Reactions:

Frequency not defined: Local: Injection site reactions

<1%: Allergic reactions, anaphylactic-like reactions (retrobulbar block or I.V. injections), angioedema, urticaria

Overdosage/Toxicology:

Drug Interactions:

Local anesthetics: Hyaluronidase may increase absorption and toxicity of local anesthetics.

Stability:

Amphadase™: Store in refrigerator at 2°C to 8°C (35°F to 46°F); do not freeze

Vitrase®: Store unopened vial in refrigerator at 2°C to 8°C (35°F to 46°F). Add 6.2 mL of NaCL to vial (1000 units/mL); further dilute with NaCl before administration. After reconstitution, store at 20°C to 25°C (68°F to 77°F) and use within 6 hours.

For 50 units/mL, draw up 0.05 mL of hyaluronidase reconstituted solution (1000 units/mL) and add 0.95 mL of NaCl.

For 75 units/mL, draw up 0.075 mL of hyaluronidase reconstituted solution and add 0.925 mL of NaCl.

For 150 units/mL, draw up 0.15 mL of hyaluronidase reconstituted solution and add 0.85 mL of NaCl.

For 300 units/mL, draw up 0.3 mL of hyaluronidase reconstituted solution and add 0.7 mL of NaCl.

Compatibility:

Compatibility in syringe: Compatible: Diatrizoate meglumine 34.3%, diatrizoate sodium 35%, iothalamate meglumine 60%, iothalamate sodium 80%, pentobarbital, thiopental. Incompatible: Hydromorphone. Variable (consult detailed reference): Diatrizoate meglumine 52%, diatrizoate sodium 8%, diatrizoate sodium 75%, iodipamide meglumine 52%

Compatibility when admixed: Compatible: Amikacin, sodium bicarbonate. Incompatible: Epinephrine, heparin

Mechanism of Action:

Pharmacodynamics/Kinetics:

Onset of action: SubQ: Immediate

Duration: 24-48 hours

Dosage:

Skin test: Intradermal: 0.02 mL (3 units) of a 150 units/mL solution. Positive reaction consists of a wheal with pseudopods appearing within 5 minutes and persisting for 20-30 minutes with localized itching.

Hypodermoclysis: SubQ: 15 units is added to each 100 mL of I.V. fluid to be administered

Premature Infants and Neonates: Volume of a single clysis should not exceed 25 mL/kg and the rate of administration should not exceed 2 mL/minute

Children <3 years: Volume of a single clysis should not exceed 200 mL

Children 3 years and Adults: Rate and volume of a single clysis should not exceed those used for infusion of I.V. fluids

Extravasation (unlabeled use): Adults: SubQ: Inject 1 mL of a 150 unit/mL solution (as 5-10 injections of 0.1-0.2 mL) into affected area; doses of 15-250 units have been reported.

Elderly: See Adults dosing. Adjust dose carefully to individual patient.

Administration:

Patient Education:

Dental Health: Effects on Dental Treatment:

Dental Health: Vasoconstrictor/Local Anesthetic Precautions:

Mental Health: Effects on Mental Status:

Mental Health: Effects on Psychiatric Treatment:

Dosage Forms:

Injection, powder for reconstitution (Vitrase®): 6200 units [ovine derived; contains lactose]

Injection, solution (Amphadase™): 150 units/mL (2 mL) [bovine derived; contains edetate disodium 1 mg, thimerosal 0.1 mg]

Injection, solution [preservative free] (Vitrase®): 200 units/mL (2 mL) [ovine derived; contains lactulose]

International Brand Names: